share_log

Xencor, UCLA Ink Collaboration Pact For XmAb Therapeutic Candidates

Xencor, UCLA Ink Collaboration Pact For XmAb Therapeutic Candidates

Xencor,加州大学洛杉矶分校(UCLA)针对XmAb候选治疗的墨水合作协定
Benzinga Real-time News ·  2021/02/25 20:15
  • Xencor Inc (NASDAQ: XNCR) and UCLA Technology Development Group have agreed to develop novel therapeutic antibodies utilizing Xencor's modular suite of XmAb technology platforms. 
  • Xencor's XmAb platforms are precisely engineered antibody Fc domains, which enable the creation of stable new protein structures. Xencor and its pharmaceutical partners are now advancing 20 clinical-stage XmAb-engineered drug candidates to treat various life-threatening and debilitating diseases.
  • UCLA will work to propose potential antibody drug candidates. The collaborators will use a framework with predefined terms to enter sponsored research agreements and potential license agreements for selected candidates.
  • Price Action: XNCR closed 0.3% higher at $48.5 on Wednesday.
  • Xencor Inc.(纳斯达克:XNCR)和加州大学洛杉矶分校技术开发集团(UCLA Technology Development Group)同意开发采用Xencor模块化XmAb技术平台的新型治疗性抗体。
  • Xencor的XmAb平台是精确设计的抗体Fc结构域,能够创建稳定的新蛋白质结构。Xencor及其制药合作伙伴现在正在推进20种临床阶段的XmAb工程药物候选药物,用于治疗各种威胁生命和虚弱的疾病。
  • 加州大学洛杉矶分校(UCLA)将致力于提出潜在的抗体药物候选方案。合作者将使用一个带有预定义条款的框架,为选定的候选人输入赞助研究协议和潜在的许可协议。
  • 价格行动:XNCR周三收高0.3%,报48.5美元。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发